Tag: Eli Lilly

Weekly Update

Weekly Market Overview – August 3-August 9, 2026

Palantir impresses with strong growth. The UMBRELLA strategy also focuses on healthcare, European defense, and structural trends.
Continue Umbrella
Weekly Update

Weekly Market Overview – August 17-August 23, 2026

Healthcare and AI provided support in a mixed week, while European defense stocks and SpaceX were more under pressure. There
Continue Umbrella
Weekly Update

Weekly Market Overview – August 24–August 30, 2026

Revolution Medicines reaches a major milestone with the FDA approval of RASONQUE, while PayPal saw significant price fluctuations following the
Continue Umbrella
Weekly Update

Weekly Market Overview – August 10-August 16, 2026

TKMS raises its outlook, SpaceX is added to the UMBRELLA strategy, thereby strengthening its focus on defense, AI, and the
Continue Umbrella
Weekly Update

Weekly Market Overview – July 27-August 2, 2026

The market overview shows why strong figures from Apple, Rheinmetall, and other companies are not always enough for price gains.
Continue Umbrella
Weekly Update

Weekly Market Overview – July 20-26, 2026

Tesla is at the center of the earnings season following its Q2 results. The UMBRELLA Strategy is selling the position
Continue Umbrella
Weekly Update

Weekly Market Overview – July 13-19, 2026

IBM's earnings warning rattles the stock markets. Why fundamental data, quarterly results, and company outlooks are once again the most
Continue Umbrella
Weekly Update

Weekly Market Overview – June 8-14, 2026

AI and healthcare innovation are shaping the markets. The UMBRELLA Strategy increases its focus on quality companies and reduces cyclical
Continue Umbrella
Weekly Update

Weekly Market Overview – June 1-7, 2026

The UMBRELLA strategy has completed its portfolio restructuring, further strengthening its focus on Artificial Intelligence, cloud infrastructure, and data analysis.
Continue Umbrella
Weekly Update

Weekly Market Overview – May 25–31, 2026

The UMBRELLA Strategy is placing a stronger emphasis on AI, technology, healthcare, and defense. Tesla remains the largest single position.
Continue Umbrella
Eli Lilly
Healthcare
USA

Valuation Analysis: Eli Lilly and Company

Eli Lilly reported an exceptionally strong Q2 2026. Growth and higher guidance impress, but valuation, pricing pressure, and cash flow
Active icon
Continue Umbrella
Eli Lilly
Healthcare
USA

Stock: Eli Lilly and Company

Eli Lilly is one of the leading pharmaceutical companies worldwide. Growth drivers include Mounjaro, Zepbound, and a strong pipeline in
Active icon
Continue Umbrella